Drug Profile
Vonoprazan - Takeda
Alternative Names: TAK-438; TAKECAB; VOCINTI; Vocinti; VONOPION®; Vonoprazan fumarate; VONOSAP®; VOQUEZNA; VOQUEZNA DUAL PAK; VOQUEZNA TRIPLE PAKLatest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Takeda
- Developer Phathom Pharmaceuticals; Takeda
- Class Amines; Anti-inflammatories; Antibacterials; Antiulcers; Pyridines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
- Phase III Gastrointestinal disorders
Most Recent Events
- 07 Mar 2024 Phathom plans a phase II trial for Eosinophilic Esophagitis (In adults, In adolescents) in 2024
- 06 Dec 2023 Phathom Pharmaceuticals plans a phase III trial for Gastro-oesophageal reflux (PO) in USA in 2024
- 06 Dec 2023 The US FDA accepts NDA for vonoprazan for Gastro-oesophageal reflux for review